ADMA

ADMA Biologics, Inc.

Fundamental data last updated:July 26, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/05/2026

Business Summary

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

 


Analyze ADMA on TradingView

VALUATION

P/E

11.32

Market Cap ($M USD)

$1.84B

Forward P/E

3.98

PEG

0.02

PRICE TO SALES

3.60

PRICE TO BOOK

4.80

EV / EBITDA

8.96

5-Year Average P/E

Free Cash Flow Yield

5.87%

DCF Value

$-119.61

Graham Number

$5.10

Price to FCF

17.03

EV to FCF

17.65

Earnings Yield

8.83%

FCF Yield

5.87%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$0.70

Next Year EPS Growth Estimate

$1.99

Next Year Revenue Growth Estimate

$107.60B

Return on Equity (ROE)

38.97%

FREE CASH FLOW

Operating Margin

40.57%

Debt-to-Equity

0.17

Piotroski F-Score

6

Altman Z-Score

6.33

Return on Invested Capital (ROIC)

34.96%

Current Ratio

6.95

Quick Ratio

3.93

Net Debt to EBITDA

0.31

Interest Coverage

28.59

Gross Profit margin

61.27%

FCF PER SHARE

$0.46

REVENUE PER SHARE

$2.16

Analyze ADMA on TradingView

Gainseekers Quantitative Analysis

Summary

ADMA Biologics presents a perplexing valuation scenario. Despite a DCF value that suggests significant overvaluation, the market has priced the stock with a Forward P/E of 4.11, indicating expectations of robust earnings growth. The Altman Z-score of 6.46 highlights financial stability, while an Earnings Yield of 8.57% suggests decent returns relative to the price. However, the Graham Number implies a more conservative valuation, raising questions about the market’s optimism. The stock’s financial health is underscored by a strong Return on Equity of 38.97%, reflecting efficient management.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, ADMA Biologics is well-positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's inherent focus on innovation aligns with tech-driven shifts, potentially enhancing R&D efficiency. However, the pace of adaptation will be crucial in maintaining competitive advantage.

The Bull Case

For the value-driven investor, ADMA Biologics offers compelling reasons to buy. A stellar ROIC of 34.96% and a robust Operating Margin of 40.57% indicate strong capital efficiency and pricing power. The Piotroski F-Score of 6 suggests solid financial health, while a Free Cash Flow Yield of 5.70% reflects potential for shareholder returns. These metrics paint a picture of a company capable of generating substantial cash flow and reinvesting effectively.

The Bear Case

Despite its strengths, ADMA Biologics is not without risks. The Price/Book ratio of 4.94 and Price/Sales ratio of 3.71 suggest the stock might be overvalued relative to its assets and revenue. Additionally, the stock's proximity to its 52-week high raises concerns about technical overextension. While debt levels are manageable, the negative earnings surprise indicates potential volatility in earnings performance.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$21.00

Institutional Ownership %

1-Year Beta

0.82

Insider Buying % (6 Mo)

Distance to 52-Week High

182.09%

Distance to 52-Week Low

9.08%

EARNINGS SURPRISE %

-1.71%

50-DAY SMA

$9.95

200-DAY SMA

$15.00

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.